Results 41 to 50 of about 352 (104)

Successful Treatment of Evans Syndrome Onset With Zanubrutinib in Combination With Romiplostim During Venetoclax Treatment in a Patient With Chronic Lymphocytic Leukemia: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) can be complicated by autoimmune cytopenias, including autoimmune hemolytic anemia and immune thrombocytopenia (ITP), as observed in Evans syndrome. We report the case of a 75‐year‐old man with CLL who developed steroid‐ and rituximab‐refractory Evans syndrome during the ramp‐up phase of venetoclax treatment.
Vanessa Innao, Alessia Paola Maria Barbagallo, Oriana Bianco, Valerio Leotta, Ugo Consoli   +4 more
wiley   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL‐2/BCL‐XL Inhibition

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Simultaneous blockade of the anti‐apoptotic proteins BCL‐2 and BCL‐XL has been shown to be efficacious in preclinical and clinical trials for tumors that are co‐dependent on their survival pathways, although clinical development has been limited owing to dose‐limiting thrombocytopenia associated with BCL‐XL inhibition.
Md Mohiuddin
wiley   +1 more source

Efficacy and safety of romiplostim in adult Iraqi patients with refractory immune thrombocytopenia

Iraqi Journal of Hematology, 2020
BACKGROUND: Immune thrombocytopenia (ITP) is an immune-mediated acquired disease characterized by decrease of the platelet count. The majority of adult patients progress to chronic stage with some of them failed to respond or relapsed after the second ...
Ali Khazaal Jumaa, Tareq Abdullah Saleh, Asaad Abdulameer Khalaf, Mohammed Saleem Abbas   +3 more
doaj   +1 more source

Personalized Management of Cytopenias in Chronic Liver Disease: From Pathophysiology to Treatment Strategies

JGH Open, Volume 10, Issue 5, May 2026.
ABSTRACT Thrombocytopenia and leukopenia are among the most common hematological abnormalities in patients with chronic liver disease (CLD), particularly among those with cirrhosis. Thrombocytopenia and leukopenia are associated with increased risks of bleeding, infection, treatment delay, and poor clinical outcomes.
Xiaoxiao Wang, Shuyan Fu, Xiaohong Zhu, Yanping Zhao   +3 more
wiley   +1 more source

PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE

Mediterranean Journal of Hematology and Infectious Diseases, 2012
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage.
Simone Baldini, Luigi Rigacci, Valentina Carrai, Renato Alterini, Rajmonda Fjerza, Alberto Bosi   +5 more
doaj   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

From Immunization to Autoimmunity: A Deep Dive Into Post‐COVID‐19 Vaccine Reactions—A Narrative Review

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Coronavirus disease‐2019 (COVID‐19) emerged in 2019 from Wuhan, China, leading to the accelerated development of vaccines, which have proven instrumental in controlling the spread of the virus. While vaccination ceased the increasing trend of the viral infection, rare adverse autoimmune events emerged as important ...
Mohammad Javad Yousefi‐Hashemabad, Saeed Hashemi, Kiarash Saleki, Seyed Mohamad Kazem Nourbakhsh, Andia Saleki, Zahra Hassanzadeh, Abbas Azadmehr   +6 more
wiley   +1 more source

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

Haematologica, 2013
Romiplostim and eltrombopag, the first thrombopoietic receptor-agonists with demonstrated efficacy against immune thrombocytopenia in prospective controlled studies, were recently authorized in most countries for adults with chronic immune ...
Mehdi Khellaf, Jean-François Viallard, Mohamed Hamidou, Stéphane Cheze, Françoise Roudot-Thoraval, François Lefrere, Olivier Fain, Sylvain Audia, Jean-François Abgrall, Jean-Marie Michot, Charles Dauriac, Sophie Lefort, Emmanuel Gyan, Mathilde Niault, Jean-Marc Durand, Laetitia Languille, David Boutboul, Philippe Bierling, Marc Michel, Bertrand Godeau   +19 more
doaj   +1 more source

Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain

Case Reports in Hematology, 2017
Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80–90% of patients achieving platelet responses after few weeks of treatment.
María-Eva Mingot-Castellano, Carlos Grande-García, David Valcárcel-Ferreiras, Clara Conill-Cortés, Loreto de Olivar-Oliver   +4 more
doaj   +1 more source